glp-1 insomnia Medications Show Promise as First Drug Therapy for Sleep Apnea GLP-1 Sleep Changes: What Real

While significant progress has been made, further research is required to develop therapies that can effectively halt or reverse disease progression, ultimately improving the lives of individuals with DN

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

You may have been reading a lot about newly launched obesity drugs and I covered some of this in my podcast last year with Stephan Guyenet in anticipation

Women with T2DM have a similarly high risk for pregnancy complications as pregnant women with type 1 diabetes...

The yerba mate market is set to grow from US$2.1 Bn in 2026 to US$3.0 Bn by 2033, driven by rising demand and a steady 5.2% CAGR